Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial

被引:2
|
作者
Matsuura, Nozomi [1 ]
Kanayama, Masaya [1 ]
Watanabe, Yuta [1 ]
Yamada, Hirokazu [2 ,3 ]
Lili, Loukia [4 ]
Torii, Akira [5 ]
机构
[1] Kirin Holdings Co Ltd, Inst Hlth Sci, Hlth Sci Business Div, Fujisawa, Kanagawa 2518555, Japan
[2] Soiken Inc, Tokyo, Tokyo 1010052, Japan
[3] EviPRO Co Ltd, Tokyo, Tokyo 1010032, Japan
[4] Thorne HealthTech Inc, New York, NY 10019 USA
[5] Torii Med Clin, Tokyo, Tokyo 1570066, Japan
关键词
irritable bowel syndrome; personalized; microbiome; prebiotics; probiotics; PLACEBO-RESPONSE RATE; DOUBLE-BLIND; GUT MICROBIOTA; SEVERITY; LACTOBACILLUS; JAPANESE;
D O I
10.3390/nu16193333
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background/Objectives: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients. Methods: Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4. Results:The IBS-severity scoring system significantly decreased in all patients (-38.0 [95% confidence interval (CI): -53.6, -22.4]; p < 0.001), in patients with IBS-D (-44.5 [95% CI: -70.6, -18.5]; p = 0.004) and IBS-C (-51.2 [95% CI: -79.4, -22.9]; p = 0.002), but not in those with IBS-M (-20.0 [95% CI: -48.0, 8.1]; p = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention. Conclusions: In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Effect of the Probiotic Saccharomyces boulardii on Cholesterol and Lipoprotein Particles in Hypercholesterolemic Adults: A Single-Arm, Open-Label Pilot Study
    Ryan, Jennifer Joan
    Hanes, Douglas Allen
    Schafer, Morgan Beth
    Mikolai, Jeremy
    Zwickey, Heather
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2015, 21 (05) : 288 - 293
  • [22] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
    Zhengbo Song
    Guangyuan Lou
    Yina Wang
    Zhiping Yang
    Wenxian Wang
    Yongling Ji
    Shiqing Chen
    Chunwei Xu
    Xiao Hu
    Yiping Zhang
    BMC Medicine, 20
  • [23] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Kjetil Boye
    Alessandra Longhi
    Tormod Guren
    Susanne Lorenz
    Stine Næss
    Michela Pierini
    Ingeborg Taksdal
    Ingvild Lobmaier
    Marilena Cesari
    Anna Paioli
    Ayca M. Løndalen
    Elisabetta Setola
    Ivar Hompland
    Leonardo A. Meza-Zepeda
    Kirsten Sundby Hall
    Emanuela Palmerini
    Cancer Immunology, Immunotherapy, 2021, 70 : 2617 - 2624
  • [24] Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial
    Kroiss, Matthias
    Quinkler, Marcus
    Johanssen, Sarah
    van Erp, Nielka P.
    Lankheet, Nienke
    Poellinger, Alexander
    Laubner, Katharina
    Strasburger, Christian J.
    Hahner, Stefanie
    Mueller, Hans-Helge
    Allolio, Bruno
    Fassnacht, Martin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (10): : 3495 - 3503
  • [25] Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial
    Chen, Yuxi
    Pan, Yuan
    Xie, Yanyan
    Shi, Yuxun
    Lu, Yao
    Xia, Yiwen
    Su, Wenru
    Chen, Xiaoqing
    Li, Zuoyi
    Wang, Minzhen
    Miao, Siyu
    Yang, Yating
    Jin, Chenjin
    Luo, Guangwei
    Long, Shixian
    Xiao, Hui
    Huang, Chuangxin
    Zhang, Jian
    Liang, Dan
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [26] Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
    Brastianos, Priscilla K.
    Lee, Eudocia Quant
    Cohen, Justine V.
    Tolaney, Sara M.
    Lin, Nancy U.
    Wang, Nancy
    Chukwueke, Ugonma
    White, Michael D.
    Nayyar, Naema
    Kim, Albert
    Alvarez-Breckenridge, Christopher
    Krop, Ian
    Mahar, Maura Keeley
    Bertalan, Mia S.
    Shaw, Brian
    Mora, Joana L.
    Goss, Nathaniel
    Subramanian, Megha
    Nayak, Lakshmi
    Dietrich, Jorg
    Forst, Deborah A.
    Nahed, Brian V.
    Batchelor, Tracy T.
    Shih, Helen A.
    Gerstner, Elizabeth R.
    Moy, Beverly
    Lawrence, Donald
    Giobbie-Hurder, Anita
    Carter, Scott L.
    Oh, Kevin
    Cahill, Daniel P.
    Sullivan, Ryan J.
    NATURE MEDICINE, 2020, 26 (08) : 1280 - +
  • [27] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Boye, Kjetil
    Longhi, Alessandra
    Guren, Tormod
    Lorenz, Susanne
    Naess, Stine
    Pierini, Michela
    Taksdal, Ingeborg
    Lobmaier, Ingvild
    Cesari, Marilena
    Paioli, Anna
    Londalen, Ayca M.
    Setola, Elisabetta
    Hompland, Ivar
    Meza-Zepeda, Leonardo A.
    Hall, Kirsten Sundby
    Palmerini, Emanuela
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (09) : 2617 - 2624
  • [28] Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial
    Lembo, Anthony
    Kelley, John M.
    Nee, Judy
    Ballou, Sarah
    Iturrino, Johanna
    Cheng, Vivian
    Rangan, Vikram
    Katon, Jesse
    Hirsch, William
    Kirsch, Irving
    Hall, Kathryn
    Davis, Roger B.
    Kaptchuk, Ted J.
    PAIN, 2021, 162 (09) : 2428 - 2435
  • [29] Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan
    Morioka, Ichiro
    Kakei, Yasumasa
    Omori, Takashi
    Nozu, Kandai
    Fujioka, Kazumichi
    Takahashi, Naoto
    Yoshikawa, Tetsushi
    Moriuchi, Hiroyuki
    Ito, Yoshinori
    Oka, Akira
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (13)
  • [30] Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache: An Open-label, Single-Arm, Clinical Trial
    Di Lorenzo, Cherubino
    Coppola, Gianluca
    Di Lenola, Davide
    Evangelista, Maurizio
    Sirianni, Giulio
    Rossi, Paolo
    Di Lorenzo, Giorgio
    Serrao, Mariano
    Pierelli, Francesco
    FRONTIERS IN NEUROLOGY, 2018, 9